Table 6.
Significantly depleted human TFs for the upregulated genes in the EMT process
| Human TFs | PMID | # total TGs | # DETGs | Fold ratio | Corrected p-value | Cell lines |
|---|---|---|---|---|---|---|
| ELF1 | 17652178 | 99 | 0 | Inf | <3.45E-14 | JURKAT |
| GABP | 17652178 | 655 | 9 | 4.6 | 2.2E-08 | JURKAT |
| EST1 | 17652178 | 636 | 9 | 4.5 | 6.4E-08 | JURKAT |
| ETS1 | 20019798 | 1446 | 28 | 3.3 | 2.8E-14 | JURKAT |
| KDM6A | 18722178 | 410 | 9 | 2.9 | 7.4E-03 | U937_AND_SAOS2 |
| FOXP3 | 21729870 | 1300 | 43 | 1.9 | 6.1E-05 | TREG |
| VDR | 23849224 | 2029 | 69 | 1.9 | 9.1E-08 | CD4+ |
| GABP | 19822575 | 2430 | 92 | 1.7 | 7.2E-07 | HepG2 |
| HOXC9 | 25013753 | 1858 | 72 | 1.6 | 1.7E-04 | NEUROBLASTOMA BE2-C |
The depleted transcription factors (TFs) were inferred by comparing ChIP-Seq or ChIP-chip identified target genes (TGs) of each TF with the upregulated DEGs in the EMT process. Depleted TFs were sorted according to the depleted fold ratios
PMID pubmed article number; # total TGs number of ChIP-Seq or ChIP-chip identified target genes (TGs) of each TF; #DETGs number of differentially expressed genes